BLC
CRL icon

Brown, Lisle/Cummings’s Charles River Laboratories CRL Stock Holding History

Brown, Lisle/Cummings’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680 Sell
3
-4
-57% -$712 ﹤0.01% 992
2026
Q1 		$1.21K Buy
+7
New +$1.3K ﹤0.01% 905

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Brown, Lisle/Cummings's CRL Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Charles River Laboratories (CRL) stake by 57% in Q2 2026, selling an estimated $712 and leaving 3 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #992.

Brown, Lisle/Cummings first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.21K in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Brown, Lisle/Cummings held 3 shares of Charles River Laboratories worth $680 as of Q2 2026.
  • Brown, Lisle/Cummings sold 4 Charles River Laboratories shares in Q2 2026, an estimated $712.
  • Charles River Laboratories made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #992 holding.
  • Brown, Lisle/Cummings first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • Brown, Lisle/Cummings's Charles River Laboratories position peaked at $1.21K in Q1 2026.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.